Rapid communicationThe effect of statin therapy on lipoprotein associated phospholipase A2 levels
Introduction
Lp-PLA2 is a calcium independent member (distinguished from secretory PLA2, a calcium dependent enzyme) of the phospholipase A2 enzyme family that is believed to play a role in the development of atherosclerosis. Also known as platelet activating factor acetylhyrolase, Lp-PLA2 is principally produced by hematopoietic cells including macrophages, monocytes and mast cells [1], [2]. Mechanistically, Lp-PLA2 hydrolyzes oxidatively altered phospholipids that have shortened sn2 fatty acids to produce oxidized fatty acids and lysophosphatidylcholine, a function that deems Lp-PLA2 a pro-atherogenic agent. Additionally, through its role in hydrolyzing and thus inactivating platelet activating factor, Lp-PLA2 also has an anti-inflammatory function [2], [3]. In plasma, most Lp-PLA2 is bound to pro-atherogenic small, dense, LDL particles while a small fraction is associated with high-density lipoprotein cholesterol (HDL-C).
At the population level, the association between risk of cardiovascular disease (CVD) and Lp-PLA2 remains the subject of ongoing evaluation. Both the West of Scotland Coronary Prevention (WOSCOPS) and the Atherosclerosis Risk in Communities (ARIC) studies suggest a relationship between elevated levels of Lp-PLA2 and increased risk of CVD [4], [5]. Also, a study by Koenig et al. indicated that elevated levels of Lp-PLA2 were associated with increased risk of coronary events [6]. By contrast, data from the Women's Health Study found little evidence of independent association between CVD and Lp-PLA2 levels [7], and in a Japanese study, deficiency of plasma Lp-PLA2 due to a point mutation in G994 → T in the Lp-PLA2 gene resulted in decreased enzyme activity and a reported increase in risk of vascular disease [8].
Since Lp-PLA2 is primarily bound to LDL-C and probably influences the development of foam cells and other oxidatively charged molecules involved in atherosclerosis, it is of potential clinical importance to understand the effect of statin therapy on Lp-PLA2 levels. We, therefore, examined the role of statin treatment in reducing Lp-PLA2 levels among 481 individuals treated for 12 weeks with pravastatin.
Section snippets
Methods
The study population was derived from participants in the Pravastatin/CRP Evaluation (PRINCE) trial, a multicenter, community-based trial that examined the effect of pravastatin 40 mg daily on CRP levels among individuals with and without cardiovascular disease (history of myocardial infarction, stroke or coronary revascularization) [9]. Individuals with a history of a chronic inflammatory condition, need for anti-inflammatory therapy, use of statin therapy within 6 months prior to enrollment or
Results
Baseline clinical characteristics of the 481 study participants are shown in Table 1. With the exception of current smokers and diastolic blood pressure, no significant differences were observed at baseline between the pravastatin and placebo groups. Current smoking was somewhat more prevalent in the placebo group while those in the pravastatin group had higher diastolic blood pressure. There were no significant differences in baseline median Lp-PLA2 levels between the pravastatin treated (282.8
Discussion
In this randomized, placebo controlled study, we found that pravastatin resulted in a significant reduction in median Lp-PLA2 levels compared to placebo among individuals who were free of cardiovascular disease. This finding was consistent among all subgroups evaluated. As also shown in these data, much of this effect is mediated through statin effect on LDL-C. Our data adds to the emerging literature on Lp-PLA2 by demonstrating the noted effects of statin therapy in a sizable randomized
Acknowledgements
Dr. Albert is supported by an award from the Robert Wood Johnson Foundation. Both Drs. Albert and Ridker are supported by a grant from the Donald W. Reynolds Foundation.
The PRINCE trial was investigator initiated, coordinated and performed centrally within the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, and was run with full independence. The research group wrote all the protocols and manuals, holds all the primary data forms, and
References (20)
- et al.
Inflammation bioactive lipids and atherosclerosis: potential roles of a lipoprotein associated phospholipase Az, platelet activating factor acetylhydrolase
Atherorsclerosis
(2002) - et al.
A prospective evaluation of lipoprotein associated phospholipase A2 levels and the risk of future cardiovascular events in women
J Am Coll Cardiol
(2001) - et al.
Identification of the G994 → T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent factor for coronary artery disease in Japanese men
Metabolism
(1998) - et al.
Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment
J Lipid Mediators Cell Signal
(1997) - et al.
Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apo-B containing lipoproteins
J Lipid Res
(2003) - et al.
Determinants of plasma platelet activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins
J Lipid Res
(1997) - et al.
Expression of plasma platelet activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation
J Biol Chem
(1998) - et al.
Effects of endotoxins and cytokines on the secretion of platelet activating factor acetylhydrolase by human decidual macrophages
Am J Ostet Gynecol
(1993) - et al.
Cell specific regulation of expression of plasma type platelet activating factor acetylhydrolase in the liver
J Biol Chem
(1997) - et al.
Lipoprotein associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease
Curr Opin Lipid
(2003)
Cited by (87)
Phospholipase A2 in cardiovascular disease
2023, Phospholipases in Physiology and Pathology: Volumes 1-7LDL subclass lipidomics in atherogenic dyslipidemia: Effect of statin therapy on bioactive lipids and dense LDL
2020, Journal of Lipid ResearchLipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis
2017, Clinica Chimica ActaCitation Excerpt :Statins have been shown to reduce the level of Lp-PLA2 activity. Data from the Pravastatin OR atorVastatin Evaluation and Infection Therapy study showed that treatment with atorvastatin 80 mg/d correlated with a 20% reduction in Lp-PLA2 activity at 30 days, whereas Lp-PLA2 increased by 3.6% with 40 mg/d pravastatin [35,36]. The Heart Protection Study (HPS) also showed that simvastatin reduced Lp-PLA2 activity by 25%, but the effects of simvastatin on vascular outcomes did not vary according to Lp-PLA2 levels.
Lp-PLA<inf>2</inf>, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques
2016, Annales Pharmaceutiques Francaises